Upstream Bio, Inc. (UPB)
NASDAQ:UPB
Want to see UPB full AI Analyst Report?
UPB Stock Chart & Stats
$30.30
$0.36(1.20%)
At close: 4:00 PM EST
$30.30
$0.36(1.20%)
Day’s Range― - ―
52-Week Range$5.85 - $33.68
Previous CloseN/A
Volume30.66K
Average Volume (3M)592.28K
Market Cap
$331.96M
Enterprise Value$359.34M
Total Cash (Recent Filing)$294.58M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 12, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding54,419,987
10 Day Avg. Volume725,443
30 Day Avg. Volume592,282
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue108.17
Enterprise Value/Gross Profit109.79
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$38.43Price Target Upside26.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.87
Revenue Forecast (FY)$2.18M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt-to-equity (~0.4%) provides durable financial flexibility for a clinical-stage biotech. Low leverage reduces near-term solvency risk, supports continued R&D spending, enables opportunistic partnerships or acquisitions, and lengthens runway before debt financing becomes necessary.
Improving Revenue And Solid Gross MarginsTTM revenue growth (~16%) combined with ~66% gross margin suggests the company’s core biologic economics are attractive. For a development-stage firm, growing top-line and healthy gross margins indicate future revenues could scale efficiently and help leverage fixed R&D and G&A over time.
Governance Continuity And OversightSuccessful director elections and ratification of PwC reinforce governance continuity and independent oversight. Stable board composition and an established auditor strengthen financial controls and strategic decision-making, supporting sustainable corporate governance through clinical development cycles.
Bears Say
Worsening Cash BurnOperating and free cash flows are deeply negative and have deteriorated versus prior years, signaling rising cash consumption. Persistent and worsening burn materially shortens runway, forces repeated financing, and limits ability to fund trials or expand operations without dilutive or costly capital raises.
Deep And Growing LossesThe firm is deeply loss-making with large operating and net losses and deteriorating margins as expenses scale faster than revenue. Continued negative profitability undermines return generation, constrains reinvestment efficiency, and makes sustainable earnings unlikely until clinical or partnership successes alter revenue trajectories.
Equity Dilution / Funding RelianceThe $150M ATM program provides capital access but creates a structural dilution pathway if drawn. Reliance on equity financing can dilute existing holders, influence capital allocation decisions, and reduce long-term per-share value if frequent issuances are needed to offset persistent cash burn.
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $5.85 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $331.96M.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 58 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on May 13, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.02.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate is -0.74.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,419,987 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 4.581%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Upstream Bio, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.43 (26.83% Upside)
$38.43 (26.83% Upside)
Blogger Sentiment
Bullish
UPB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.23%
12-Months-Change
Fundamentals
Return on Equity
-43.82%
Trailing 12-Months
Asset Growth
-30.28%
Trailing 12-Months
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
UPB Stock 12 Month Forecast
Average Price Target
$38.43
▲(26.83% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.69% Insiders
19.44% Mutual Funds
34.74% Other Institutional Investors
29.08% Public Companies and
Individual Investors